Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Unicycive Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 24 | 1 | 29 | +6 |
| Shares | 19.0M | 51.8K | 46.8M | +27.8M (+147.0%) |
| Value | $9.52M | $26.0K | $19.1M | +$9.59M (+101.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Great Point Partners LLC | 8,559,000 | $3.49M | 1.05% |
| Octagon Capital Advisors LP | 8,559,000 | $3.49M | 0.56% |
| Walleye Capital LLC | 5,000,000 | $2.04M | 0.02% |
| Silverarc Capital Management, LLC | 4,000,000 | $1.63M | 0.37% |
| Alyeska Investment Group, L.P. | 2,250,000 | $917.8K | 0.00% |
| Acuta Capital Partners, LLC | 1,979,199 | $807.3K | 0.65% |
| Altium Capital Management LP | 1,473,000 | $600.8K | 0.18% |
| Bleakley Financial Group, LLC | 80,000 | $32.6K | 0.00% |
| BlackRock, Inc. | 71,821 | $29.3K | 0.00% |
| XTX Topco Ltd | 70,784 | $28.9K | 0.00% |
| Jane Street Group, LLC | 41,249 | $16.8K | 0.00% |
| Two Sigma Securities, LLC | 23,266 | $9.49K | 0.00% |
| Creative Planning | 10,231 | $4.17K | 0.00% |
Sold out (7)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Ra Capital Management, L.P. | 2,632,200 | $1.32M |
| BVF Inc | 2,200,000 | $1.10M |
| Rosalind Advisors, Inc. | 1,571,200 | $787.3K |
| Monashee Investment Management LLC | 1,000,000 | $501.1K |
| Renaissance Technologies LLC | 33,200 | $16.6K |
| Scientech Research LLC | 10,969 | $5.50K |
| Redwood Wealth Management Group, LLC | 3,000 | $1.50K |
Not filed for Q3 2024 yet (1)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 51,837 | $26.0K |